カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

ナタリズマブ医薬品の世界市場2022：多発性硬化症、クローン病

■ 英語タイトル：Global Natalizumab Drug Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22DC3868）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22DC3868
■ 発行日：2023年1月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：72
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[ナタリズマブ医薬品の世界市場2022：多発性硬化症、クローン病]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

世界のナタリズマブ医薬品市場レポートは、グローバル市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
Global Info Research社の最新のリサーチによると、世界のナタリズマブ医薬品の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

ナタリズマブ医薬品市場はタイプとアプリケーションによって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

タイプ別セグメントは次をカバーします。
・多発性硬化症、クローン病

アプリケーション別セグメントは次のように区分されます。
・病院、ドラッグストア

世界のナタリズマブ医薬品市場の主要な市場プレーヤーは以下のとおりです。
・Biogen

地域別セグメントは次の地域・国をカバーします。
・北米（アメリカ、カナダ、メキシコ）
・欧州（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南米（ブラジル、アルゼンチン、コロンビア）
・中東/アフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査資料の内容は計15章あります。
・第1章では、ナタリズマブ医薬品製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なナタリズマブ医薬品メーカーの企業概要、2019年～2022年までのナタリズマブ医薬品の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なナタリズマブ医薬品メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別ナタリズマブ医薬品の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのナタリズマブ医薬品の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのナタリズマブ医薬品市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびナタリズマブ医薬品の産業チェーンを掲載しています。
・第13、14、15章では、ナタリズマブ医薬品の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
– ナタリズマブ医薬品の概要
– 種類別分析（2017年vs2021年vs2028年）：多発性硬化症、クローン病
– 用途別分析（2017年vs2021年vs2028年）：病院、ドラッグストア
– 世界のナタリズマブ医薬品市場規模・予測
– 世界のナタリズマブ医薬品生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Biogen
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：多発性硬化症、クローン病
・用途別分析2017年-2028年：病院、ドラッグストア
・ナタリズマブ医薬品の北米市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・ナタリズマブ医薬品のヨーロッパ市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・ナタリズマブ医薬品のアジア市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・ナタリズマブ医薬品の南米市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・ナタリズマブ医薬品の中東・アフリカ市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Natalizumab Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Natalizumab Drug Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Multiple Sclerosis
1.2.3 Crohn’s Disease
1.3 Market Analysis by Application
1.3.1 Overview: Global Natalizumab Drug Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Drugs Stores
1.4 Global Natalizumab Drug Market Size & Forecast
1.4.1 Global Natalizumab Drug Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Natalizumab Drug Sales in Volume (2017-2028)
1.4.3 Global Natalizumab Drug Price (2017-2028)
1.5 Global Natalizumab Drug Production Capacity Analysis
1.5.1 Global Natalizumab Drug Total Production Capacity (2017-2028)
1.5.2 Global Natalizumab Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Natalizumab Drug Market Drivers
1.6.2 Natalizumab Drug Market Restraints
1.6.3 Natalizumab Drug Trends Analysis
2 Manufacturers Profiles
2.1 Biogen
2.1.1 Biogen Details
2.1.2 Biogen Major Business
2.1.3 Biogen Natalizumab Drug Product and Services
2.1.4 Biogen Natalizumab Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Natalizumab Drug Breakdown Data by Manufacturer
3.1 Global Natalizumab Drug Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Natalizumab Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Natalizumab Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Natalizumab Drug Manufacturer Market Share in 2021
3.4.2 Top 6 Natalizumab Drug Manufacturer Market Share in 2021
3.5 Global Natalizumab Drug Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Natalizumab Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Natalizumab Drug Market Size by Region
4.1.1 Global Natalizumab Drug Sales in Volume by Region (2017-2028)
4.1.2 Global Natalizumab Drug Revenue by Region (2017-2028)
4.2 North America Natalizumab Drug Revenue (2017-2028)
4.3 Europe Natalizumab Drug Revenue (2017-2028)
4.4 Asia-Pacific Natalizumab Drug Revenue (2017-2028)
4.5 South America Natalizumab Drug Revenue (2017-2028)
4.6 Middle East and Africa Natalizumab Drug Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Natalizumab Drug Sales in Volume by Type (2017-2028)
5.2 Global Natalizumab Drug Revenue by Type (2017-2028)
5.3 Global Natalizumab Drug Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Natalizumab Drug Sales in Volume by Application (2017-2028)
6.2 Global Natalizumab Drug Revenue by Application (2017-2028)
6.3 Global Natalizumab Drug Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Natalizumab Drug Sales by Type (2017-2028)
7.2 North America Natalizumab Drug Sales by Application (2017-2028)
7.3 North America Natalizumab Drug Market Size by Country
7.3.1 North America Natalizumab Drug Sales in Volume by Country (2017-2028)
7.3.2 North America Natalizumab Drug Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Natalizumab Drug Sales by Type (2017-2028)
8.2 Europe Natalizumab Drug Sales by Application (2017-2028)
8.3 Europe Natalizumab Drug Market Size by Country
8.3.1 Europe Natalizumab Drug Sales in Volume by Country (2017-2028)
8.3.2 Europe Natalizumab Drug Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Natalizumab Drug Sales by Type (2017-2028)
9.2 Asia-Pacific Natalizumab Drug Sales by Application (2017-2028)
9.3 Asia-Pacific Natalizumab Drug Market Size by Region
9.3.1 Asia-Pacific Natalizumab Drug Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Natalizumab Drug Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Natalizumab Drug Sales by Type (2017-2028)
10.2 South America Natalizumab Drug Sales by Application (2017-2028)
10.3 South America Natalizumab Drug Market Size by Country
10.3.1 South America Natalizumab Drug Sales in Volume by Country (2017-2028)
10.3.2 South America Natalizumab Drug Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Natalizumab Drug Sales by Type (2017-2028)
11.2 Middle East & Africa Natalizumab Drug Sales by Application (2017-2028)
11.3 Middle East & Africa Natalizumab Drug Market Size by Country
11.3.1 Middle East & Africa Natalizumab Drug Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Natalizumab Drug Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Natalizumab Drug and Key Manufacturers
12.2 Manufacturing Costs Percentage of Natalizumab Drug
12.3 Natalizumab Drug Production Process
12.4 Natalizumab Drug Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Natalizumab Drug Typical Distributors
13.3 Natalizumab Drug Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Natalizumab Drug Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Natalizumab Drug Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Biogen Basic Information, Manufacturing Base and Competitors
Table 4. Biogen Major Business
Table 5. Biogen Natalizumab Drug Product and Services
Table 6. Biogen Natalizumab Drug Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Global Natalizumab Drug Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 8. Global Natalizumab Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 9. Market Position of Manufacturers in Natalizumab Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 10. Global Natalizumab Drug Production Capacity by Company, (K Units): 2020 VS 2021
Table 11. Head Office and Natalizumab Drug Production Site of Key Manufacturer
Table 12. Natalizumab Drug New Entrant and Capacity Expansion Plans
Table 13. Natalizumab Drug Mergers & Acquisitions in the Past Five Years
Table 14. Global Natalizumab Drug Sales by Region (2017-2022) & (K Units)
Table 15. Global Natalizumab Drug Sales by Region (2023-2028) & (K Units)
Table 16. Global Natalizumab Drug Revenue by Region (2017-2022) & (USD Million)
Table 17. Global Natalizumab Drug Revenue by Region (2023-2028) & (USD Million)
Table 18. Global Natalizumab Drug Sales by Type (2017-2022) & (K Units)
Table 19. Global Natalizumab Drug Sales by Type (2023-2028) & (K Units)
Table 20. Global Natalizumab Drug Revenue by Type (2017-2022) & (USD Million)
Table 21. Global Natalizumab Drug Revenue by Type (2023-2028) & (USD Million)
Table 22. Global Natalizumab Drug Price by Type (2017-2022) & (USD/Unit)
Table 23. Global Natalizumab Drug Price by Type (2023-2028) & (USD/Unit)
Table 24. Global Natalizumab Drug Sales by Application (2017-2022) & (K Units)
Table 25. Global Natalizumab Drug Sales by Application (2023-2028) & (K Units)
Table 26. Global Natalizumab Drug Revenue by Application (2017-2022) & (USD Million)
Table 27. Global Natalizumab Drug Revenue by Application (2023-2028) & (USD Million)
Table 28. Global Natalizumab Drug Price by Application (2017-2022) & (USD/Unit)
Table 29. Global Natalizumab Drug Price by Application (2023-2028) & (USD/Unit)
Table 30. North America Natalizumab Drug Sales by Country (2017-2022) & (K Units)
Table 31. North America Natalizumab Drug Sales by Country (2023-2028) & (K Units)
Table 32. North America Natalizumab Drug Revenue by Country (2017-2022) & (USD Million)
Table 33. North America Natalizumab Drug Revenue by Country (2023-2028) & (USD Million)
Table 34. North America Natalizumab Drug Sales by Type (2017-2022) & (K Units)
Table 35. North America Natalizumab Drug Sales by Type (2023-2028) & (K Units)
Table 36. North America Natalizumab Drug Sales by Application (2017-2022) & (K Units)
Table 37. North America Natalizumab Drug Sales by Application (2023-2028) & (K Units)
Table 38. Europe Natalizumab Drug Sales by Country (2017-2022) & (K Units)
Table 39. Europe Natalizumab Drug Sales by Country (2023-2028) & (K Units)
Table 40. Europe Natalizumab Drug Revenue by Country (2017-2022) & (USD Million)
Table 41. Europe Natalizumab Drug Revenue by Country (2023-2028) & (USD Million)
Table 42. Europe Natalizumab Drug Sales by Type (2017-2022) & (K Units)
Table 43. Europe Natalizumab Drug Sales by Type (2023-2028) & (K Units)
Table 44. Europe Natalizumab Drug Sales by Application (2017-2022) & (K Units)
Table 45. Europe Natalizumab Drug Sales by Application (2023-2028) & (K Units)
Table 46. Asia-Pacific Natalizumab Drug Sales by Region (2017-2022) & (K Units)
Table 47. Asia-Pacific Natalizumab Drug Sales by Region (2023-2028) & (K Units)
Table 48. Asia-Pacific Natalizumab Drug Revenue by Region (2017-2022) & (USD Million)
Table 49. Asia-Pacific Natalizumab Drug Revenue by Region (2023-2028) & (USD Million)
Table 50. Asia-Pacific Natalizumab Drug Sales by Type (2017-2022) & (K Units)
Table 51. Asia-Pacific Natalizumab Drug Sales by Type (2023-2028) & (K Units)
Table 52. Asia-Pacific Natalizumab Drug Sales by Application (2017-2022) & (K Units)
Table 53. Asia-Pacific Natalizumab Drug Sales by Application (2023-2028) & (K Units)
Table 54. South America Natalizumab Drug Sales by Country (2017-2022) & (K Units)
Table 55. South America Natalizumab Drug Sales by Country (2023-2028) & (K Units)
Table 56. South America Natalizumab Drug Revenue by Country (2017-2022) & (USD Million)
Table 57. South America Natalizumab Drug Revenue by Country (2023-2028) & (USD Million)
Table 58. South America Natalizumab Drug Sales by Type (2017-2022) & (K Units)
Table 59. South America Natalizumab Drug Sales by Type (2023-2028) & (K Units)
Table 60. South America Natalizumab Drug Sales by Application (2017-2022) & (K Units)
Table 61. South America Natalizumab Drug Sales by Application (2023-2028) & (K Units)
Table 62. Middle East & Africa Natalizumab Drug Sales by Region (2017-2022) & (K Units)
Table 63. Middle East & Africa Natalizumab Drug Sales by Region (2023-2028) & (K Units)
Table 64. Middle East & Africa Natalizumab Drug Revenue by Region (2017-2022) & (USD Million)
Table 65. Middle East & Africa Natalizumab Drug Revenue by Region (2023-2028) & (USD Million)
Table 66. Middle East & Africa Natalizumab Drug Sales by Type (2017-2022) & (K Units)
Table 67. Middle East & Africa Natalizumab Drug Sales by Type (2023-2028) & (K Units)
Table 68. Middle East & Africa Natalizumab Drug Sales by Application (2017-2022) & (K Units)
Table 69. Middle East & Africa Natalizumab Drug Sales by Application (2023-2028) & (K Units)
Table 70. Natalizumab Drug Raw Material
Table 71. Key Manufacturers of Natalizumab Drug Raw Materials
Table 72. Direct Channel Pros & Cons
Table 73. Indirect Channel Pros & Cons
Table 74. Natalizumab Drug Typical Distributors
Table 75. Natalizumab Drug Typical Customers
List of Figures
Figure 1. Natalizumab Drug Picture
Figure 2. Global Natalizumab Drug Revenue Market Share by Type in 2021
Figure 3. Multiple Sclerosis
Figure 4. Crohn's Disease
Figure 5. Global Natalizumab Drug Revenue Market Share by Application in 2021
Figure 6. Hospital
Figure 7. Drugs Stores
Figure 8. Global Natalizumab Drug Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 9. Global Natalizumab Drug Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Natalizumab Drug Sales (2017-2028) & (K Units)
Figure 11. Global Natalizumab Drug Price (2017-2028) & (USD/Unit)
Figure 12. Global Natalizumab Drug Production Capacity (2017-2028) & (K Units)
Figure 13. Global Natalizumab Drug Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Natalizumab Drug Market Drivers
Figure 15. Natalizumab Drug Market Restraints
Figure 16. Natalizumab Drug Market Trends
Figure 17. Global Natalizumab Drug Sales Market Share by Manufacturer in 2021
Figure 18. Global Natalizumab Drug Revenue Market Share by Manufacturer in 2021
Figure 19. Natalizumab Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Natalizumab Drug Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Natalizumab Drug Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Natalizumab Drug Sales Market Share by Region (2017-2028)
Figure 23. Global Natalizumab Drug Revenue Market Share by Region (2017-2028)
Figure 24. North America Natalizumab Drug Revenue (2017-2028) & (USD Million)
Figure 25. Europe Natalizumab Drug Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Natalizumab Drug Revenue (2017-2028) & (USD Million)
Figure 27. South America Natalizumab Drug Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Natalizumab Drug Revenue (2017-2028) & (USD Million)
Figure 29. Global Natalizumab Drug Sales Market Share by Type (2017-2028)
Figure 30. Global Natalizumab Drug Revenue Market Share by Type (2017-2028)
Figure 31. Global Natalizumab Drug Price by Type (2017-2028) & (USD/Unit)
Figure 32. Global Natalizumab Drug Sales Market Share by Application (2017-2028)
Figure 33. Global Natalizumab Drug Revenue Market Share by Application (2017-2028)
Figure 34. Global Natalizumab Drug Price by Application (2017-2028) & (USD/Unit)
Figure 35. North America Natalizumab Drug Sales Market Share by Type (2017-2028)
Figure 36. North America Natalizumab Drug Sales Market Share by Application (2017-2028)
Figure 37. North America Natalizumab Drug Sales Market Share by Country (2017-2028)
Figure 38. North America Natalizumab Drug Revenue Market Share by Country (2017-2028)
Figure 39. United States Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Natalizumab Drug Sales Market Share by Type (2017-2028)
Figure 43. Europe Natalizumab Drug Sales Market Share by Application (2017-2028)
Figure 44. Europe Natalizumab Drug Sales Market Share by Country (2017-2028)
Figure 45. Europe Natalizumab Drug Revenue Market Share by Country (2017-2028)
Figure 46. Germany Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Natalizumab Drug Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Natalizumab Drug Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Natalizumab Drug Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Natalizumab Drug Revenue Market Share by Region (2017-2028)
Figure 55. China Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Natalizumab Drug Sales Market Share by Type (2017-2028)
Figure 62. South America Natalizumab Drug Sales Market Share by Application (2017-2028)
Figure 63. South America Natalizumab Drug Sales Market Share by Country (2017-2028)
Figure 64. South America Natalizumab Drug Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Natalizumab Drug Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Natalizumab Drug Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Natalizumab Drug Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Natalizumab Drug Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Natalizumab Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Natalizumab Drug in 2021
Figure 76. Manufacturing Process Analysis of Natalizumab Drug
Figure 77. Natalizumab Drug Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • ナタリズマブ薬のグローバル市場展望 2023年-2029年：多発性硬化症、クローン病
  • ティサブリの世界市場2022：多発性硬化症、クローン病
  • タイサブリ薬の世界市場2022：多発性硬化症、クローン病
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22DC3868 )"ナタリズマブ医薬品の世界市場2022：多発性硬化症、クローン病" (英文：Global Natalizumab Drug Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。